BOTULINUM NEUROTOXIN-A THERAPY IN MIGRAINE

作者：Tajti Janos^*; Szok Delia; Tuka Bernadett; Csati Anett; Kuris Aniko; Majlath Zsofia; Lukacs Melinda; Vecsei Laszlo

来源：Ideggyogyaszati Szemle-Clinical Neuroscience, 2012, 65(3-4): 77-82.

• Botulinum neurotoxin-A
• chronic migraine
• prophylactic treatment

Although migraine is a common, paroxysmal, highly disabling disorder, the primary cause and the pathomechanism of migraine attacks are enigmatic. Experimental results suggest that activation of the trigeminovascular system is crucial in its pathogenesis. This activation leads to the release of vasoactive neuropeptides (calcitonin gene-related peptide - CGRP, and substance P- SP) and to neurogenic inflammation, and peripheral and central sensitisation are expressed.
Botulinum neurotoxin-A (BoNT-A), a potent toxin produced by Clostridium botulinum, affects the nervous system through specific cleavage of the soluble NSF-attachment protein receptor complex (SNARE), like synaptosomal-associated protein of 25 kDa (SNAP-25). The result of this multistage process is blockade of the presynaptic release of pain neurotransmitters such as CGRP, SP and glutamate. A pooled analysis of the data from two programmes of Phase 3 Research Evaluating Migraine Prophylaxis Therapy (PREEMPT 1 and 2) with BoNT-A in chronic migraine demonstrated significant benefit of BoNT-A over placebo with regard to the numbers of headache days and migraine episodes. BoNT-A diminished the frequency of acute headache pain medication intake, and resulted in reductions in headache impact and improvements in scores on the Migraine-Specific Quality of Life Questionnaire. The treatments with BoNT-A proved safe and were well tolerated.

• 出版日期2012-3-30